IPA ImmunoPrecise Antibodies
- 1.029
- -0.016-1.52%
ImmunoPrecise Antibodies News
ImmunoPrecise Antibodies Ltd. Subsidiary BioStrand Receives Prestigious 2024 Impact Award for Groundbreaking LENSai Technology
ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) ("ImmunoPrecise" or "IPA" or the "Company"), a leader in AI-driven biotherapeutic research and technology, today announces that its subsidiary, BioStrand, has been honored with
Express News | Biostrand, Immunoprecise Antibodies’ Subsidiary, Announces Immediate Commercial Offering of Groundbreaking Software With Customizable Interface for AI-Driven Drug Discovery
Express News | EXCLUSIVE: ImmunoPrecise Antibodies Tells Benzinga Co's Subsidiary BioStrand Announces Immediate Commercial Offering Of Software With Customizable Interface For AI-Driven Drug Discovery
IPA's Subsidiary, BioStrand, Announces Advanced Large Language Model (LLM) for Electronic Health Records (EHR)
Dirk Van Hyfte MD, PhD, Head of Technology, IPA, to present live demonstration at the InterSystems Global Summit 2024 June 9-12, 2024 - National Harbor, Maryland IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or
Epitope Binning Powered By LENSai TM Technology Can Analyze Over 5,000 Sequences With No Physical Materials Needed, Matches Classical Wet Lab Binning Results
VICTORIA, BC / ACCESSWIRE / April 22, 2024 / ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA), an AI-driven biotherapeutic research and technology company, has recently announced an expansion of its already
Express News | ImmunoPrecise Antibodies And InterSystems Partner To Leverage AI In Life Sciences
Express News | EXCLUSIVE: ImmunoPrecise Antibodies Tells Benzinga 'This Collaboration Integrates the New Vector Search Capability of the InterSystems IRIS Data Platform With IPA's Subsidiary BioStrand's LENS Platform for AI-driven Applications in Healthcare'
Express News | EXCLUSIVE: ImmunoPrecise Antibodies Tells Benzinga Co's Subsidiary BioStrand And InterSystems Announce A Collaboration For AI-Driven Healthcare Applications
ImmunoPrecise Antibodies Acquires Carterra LSA Instrument
Express News | IPA Acquires The Carterra LSA Instrument to Enhance Antibody Discovery And Bolster Its AI Developments
Press Release: IPA Acquires the Carterra LSA(R) Instrument to Enhance Antibody Discovery and Bolster Its AI Developments
IPA Acquires the Carterra LSA(R) Instrument to Enhance Antibody Discovery and Bolster Its AI Developments Significant throughput of LSA to advance IPA's diversity- and data-driven drug development an
ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) Q3 2024 Earnings Call Transcript
ImmunoPrecise Antibodies Price Target Maintained With a $5.00/Share by Benchmark
ImmunoPrecise Antibodies Price Target Maintained With a $5.00/Share by Benchmark
Express News | HC Wainwright & Co. Reiterates Buy on ImmunoPrecise Antibodies, Maintains $9 Price Target
ImmunoPrecise Antibodies Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/15/2024 480.61% HC Wainwright & Co. → $9 Reiterates Buy → Buy 09/18/2023 480.61% HC Wainwright & Co. →
Buy Rating Affirmed: ImmunoPrecise Antibodies' Growth and Innovation Drive Positive Outlook
Earnings Call: IPA Sees 20% Revenue Rise Amid Strategic Expansions
ImmunoPrecise Antibodies (IPA) has reported a 20% increase in total revenue year-over-year for the third quarter of fiscal year 2024, despite a challenging macroeconomic climate.
Earnings Call Summary | ImmunoPrecise Antibodies(IPA.US) Q3 2024 Earnings Conference
The following is a summary of the ImmunoPrecise Antibodies Ltd. (IPA) Q3 2024 Earnings Call Transcript:Financial Performance:ImmunoPrecise reported a Q3 2024 revenue of $6.2 million, a 20.3% increase
Express News | ImmunoPrecise Antibodies Q3 EPS $(0.11) Misses $(0.07) Estimate, Sales $6.22M Beat $4.50M Estimate
ImmunoPrecise GAAP EPS of -C$0.11, Revenue of C$6.2M
Analysis
Price Target
No Data
